{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:07:36Z","timestamp":1774616856258,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.7759\/cureus.63673","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:31:08Z","timestamp":1719934268000},"source":"Crossref","is-referenced-by-count":4,"title":["Cardiac Amyloidosis: A Comprehensive Review of Pathophysiology, Diagnostic Approach, Applications of Artificial Intelligence, and Management Strategies"],"prefix":"10.7759","author":[{"given":"Md Ripon","family":"Ahammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariha Noor","family":"Ananya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer MS","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017, 135:1357-77. 10.1161\/CIRCULATIONAHA.116.024438","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2020.06.033","article-title":"Transthyretin amyloid cardiomyopathy","year":"2021","unstructured":"Transthyretin amyloid cardiomyopathy. 2021, 156.126-134. 10.1016\/j.medcle.2020.06.033"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari A","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023, 118:3517-35. 10.1093\/cvr\/cvac119","journal-title":"Cardiovasc Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.09.016","article-title":"The Cardiac Amyloidosis Registry Study (CARS): rationale, design and methodology","volume":"30","author":"Stern LK","year":"2024","unstructured":"Stern LK, Grodin JL, Maurer MS, et al.. The Cardiac Amyloidosis Registry Study (CARS): rationale, design and methodology. J Card Fail. 2024, 30:669-78. 10.1016\/j.cardfail.2023.09.016","journal-title":"J Card Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez E","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al.. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015, 36:2585-94. 10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254104","article-title":"Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction","volume":"16","author":"Goland S","year":"2021","unstructured":"Goland S, Volodarsky I, Fabricant Y, et al.. Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PLoS One. 2021, 16:e0254104. 10.1371\/journal.pone.0254104","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-016-0915-z","article-title":"Pilot study for left ventricular imaging phenotype of patients over 65\u00a0years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy","volume":"32","author":"Bennani Smires Y","year":"2016","unstructured":"Bennani Smires Y, Victor G, Ribes D, et al.. Pilot study for left ventricular imaging phenotype of patients over 65\u00a0years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging. 2016, 32:1403-13. 10.1007\/s10554-016-0915-z","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari A","year":"2024","unstructured":"Porcari A, Sinagra G, Gillmore JD, Fontana M, Hawkins PN. Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy. Eur J Intern Med. 2024, 123:29-36. 10.1016\/j.ejim.2024.01.001","journal-title":"Eur J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years","author":"Ioannou A","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, et al.. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. 2022. 10.1161\/CIRCULATIONAHA.122.060852"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-023-10380-9","article-title":"Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy","volume":"29","author":"Wu D","year":"2024","unstructured":"Wu D, Chen W. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy. Heart Fail Rev. 2024, 29:511-21. 10.1007\/s10741-023-10380-9","journal-title":"Heart Fail Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00073.2021","article-title":"Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression","volume":"321","author":"Dittloff KT","year":"2021","unstructured":"Dittloff KT, Iezzi A, Zhong JX, Mohindra P, Desai TA, Russell B. Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression. Am J Physiol Heart Circ Physiol. 2021, 321:H149-60. 10.1152\/ajpheart.00073.2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10164-z","article-title":"The genetics of cardiac amyloidosis","volume":"27","author":"Arno S","year":"2022","unstructured":"Arno S, Cowger J. The genetics of cardiac amyloidosis. Heart Fail Rev. 2022, 27:1485-92. 10.1007\/s10741-021-10164-z","journal-title":"Heart Fail Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae011","article-title":"Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre","volume":"31","author":"Caponetti AG","year":"2024","unstructured":"Caponetti AG, Sguazzotti M, Accietto A, et al.. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre. Eur J Prev Cardiol. 2024, 31:866-76. 10.1093\/eurjpc\/zwae011","journal-title":"Eur J Prev Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri A","year":"2022","unstructured":"Dispenzieri A, Coelho T, Concei\u00e7\u00e3o I, et al.. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet J Rare Dis. 2022, 17:236. 10.1186\/s13023-022-02359-w","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-8-3-3","article-title":"The amyloidoses: clinical features, diagnosis and treatment","volume":"8","author":"Baker KR","year":"2012","unstructured":"Baker KR, Rice L. The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J. 2012, 8:3-7. 10.14797\/mdcj-8-3-3","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.04.013","article-title":"Cardiac amyloidosis: a practical approach to diagnosis and management","volume":"124","author":"Kapoor P","year":"2011","unstructured":"Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011, 124:1006-15. 10.1016\/j.amjmed.2011.04.013","journal-title":"Am J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-54","article-title":"Al amyloidosis","volume":"7","author":"Desport E","year":"2012","unstructured":"Desport E, Bridoux F, Sirac C, et al.. Al amyloidosis. Orphanet J Rare Dis. 2012, 7:54. 10.1186\/1750-1172-7-54","journal-title":"Orphanet J Rare Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.08.028","article-title":"Evaluation and management of the cardiac amyloidosis","volume":"50","author":"Selvanayagam JB","year":"2007","unstructured":"Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007, 50:2101-10. 10.1016\/j.jacc.2007.08.028","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson MM","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al.. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023, 81:1076-126. 10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10060256","article-title":"Invasive and non-invasive diagnostic pathways in the diagnosis of cardiac amyloidosis","volume":"10","author":"Briasoulis A","year":"2023","unstructured":"Briasoulis A, Bampatsias D, Papamichail A, Kuno T, Skoularigis J, Xanthopoulos A, Triposkiadis F. Invasive and non-invasive diagnostic pathways in the diagnosis of cardiac amyloidosis. J Cardiovasc Dev Dis. 2023, 10:10.3390\/jcdd10060256","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis","volume":"165","author":"Ng B","year":"2005","unstructured":"Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005, 165:1425-9. 10.1001\/archinte.165.12.1425","journal-title":"Arch Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia P","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al.. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021, 23:512-26. 10.1002\/ejhf.2140","journal-title":"Eur J Heart Fail"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00265-0","article-title":"Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study","volume":"6","author":"Spielvogel CP","year":"2024","unstructured":"Spielvogel CP, Haberl D, Mascherbauer K, et al.. Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study. Lancet Digit Health. 2024, 6:251-260. 10.1016\/S2589-7500(23)00265-0","journal-title":"Lancet Digit Health"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.123.015259","article-title":"Rare forms of cardiac amyloidosis: diagnostic clues and phenotype in apo AI and AIV amyloidosis","volume":"16","author":"Ioannou A","year":"2023","unstructured":"Ioannou A, Porcari A, Patel RK, et al.. Rare forms of cardiac amyloidosis: diagnostic clues and phenotype in apo AI and AIV amyloidosis. Circ Cardiovasc Imaging. 2023, 16:523-35. 10.1161\/CIRCIMAGING.123.015259","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11040118","article-title":"How artificial intelligence can enhance the diagnosis of cardiac amyloidosis: a review of recent advances and challenges","volume":"11","author":"Kamel MA","year":"2024","unstructured":"Kamel MA, Abbas MT, Kanaan CN, et al.. How artificial intelligence can enhance the diagnosis of cardiac amyloidosis: a review of recent advances and challenges. J Cardiovasc Dev Dis. 2024, 11:10.3390\/jcdd11040118","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005289","article-title":"Automated and interpretable patient ECG profiles for disease detection, tracking, and discovery","volume":"12","author":"Tison GH","year":"2019","unstructured":"Tison GH, Zhang J, Delling FN, Deo RC. Automated and interpretable patient ECG profiles for disease detection, tracking, and discovery. Circ Cardiovasc Qual Outcomes. 2019, 12:e005289. 10.1161\/CIRCOUTCOMES.118.005289","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto S","year":"2021","unstructured":"Goto S, Mahara K, Beussink-Nelson L, et al.. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun. 2021, 12:2726. 10.1038\/s41467-021-22877-8","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis","volume":"96","author":"Grogan M","year":"2021","unstructured":"Grogan M, Lopez-Jimenez F, Cohen-Shelly M, et al.. Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis. Mayo Clin Proc. 2021, 96:2768-78. 10.1016\/j.mayocp.2021.04.023","journal-title":"Mayo Clin Proc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100612","article-title":"Postdevelopment performance and validation of the artificial intelligence-enhanced electrocardiogram for detection of cardiac amyloidosis","volume":"2","author":"Harmon DM","year":"2023","unstructured":"Harmon DM, Mangold K, Suarez AB, et al.. Postdevelopment performance and validation of the artificial intelligence-enhanced electrocardiogram for detection of cardiac amyloidosis. JACC Adv. 2023, 2:10.1016\/j.jacadv.2023.100612","journal-title":"JACC Adv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3772129","article-title":"Automatic segmentation of left ventricle in echocardiography based on YOLOv3 model to achieve constraint and positioning","volume":"2021","author":"Zhuang Z","year":"2021","unstructured":"Zhuang Z, Jin P, Joseph Raj AN, Yuan Y, Zhuang S. Automatic segmentation of left ventricle in echocardiography based on YOLOv3 model to achieve constraint and positioning. Comput Math Methods Med. 2021, 2021:3772129. 10.1155\/2021\/3772129","journal-title":"Comput Math Methods Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2023.09.011","article-title":"Echocardiography-based deep learning\u00a0model to differentiate constrictive pericarditis and restrictive\u00a0cardiomyopathy","volume":"17","author":"Chao CJ","year":"2024","unstructured":"Chao CJ, Jeong J, Arsanjani R, et al.. Echocardiography-based deep learning\u00a0model to differentiate constrictive pericarditis and restrictive\u00a0cardiomyopathy. JACC Cardiovasc Imaging. 2024, 17:349-60. 10.1016\/j.jcmg.2023.09.011","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/jimaging9020048","article-title":"Developing an echocardiography-based, automatic deep learning framework for the differentiation of increased left ventricular wall thickness etiologies","volume":"9","author":"Li J","year":"2023","unstructured":"Li J, Chao CJ, Jeong JJ, et al.. Developing an echocardiography-based, automatic deep learning framework for the differentiation of increased left ventricular wall thickness etiologies. J Imaging. 2023, 9:10.3390\/jimaging9020048","journal-title":"J Imaging"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11121268","article-title":"Convolutional neural networks for fully automated diagnosis of cardiac amyloidosis by cardiac magnetic resonance imaging","volume":"11","author":"Agibetov A","year":"2021","unstructured":"Agibetov A, Kammerlander A, Duca F, et al.. Convolutional neural networks for fully automated diagnosis of cardiac amyloidosis by cardiac magnetic resonance imaging. J Pers Med. 2021, 11:10.3390\/jpm11121268","journal-title":"J Pers Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112693","article-title":"A machine learning challenge: detection of cardiac amyloidosis based on Bi-atrial and right ventricular strain and cardiac function","volume":"12","author":"Eckstein J","year":"2022","unstructured":"Eckstein J, Moghadasi N, K\u00f6rperich H, et al.. A machine learning challenge: detection of cardiac amyloidosis based on Bi-atrial and right ventricular strain and cardiac function. Diagnostics (Basel). 2022, 12:10.3390\/diagnostics12112693","journal-title":"Diagnostics (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2020.101668","article-title":"Contrast agent-free synthesis and segmentation of ischemic heart disease images using progressive sequential causal GANs","volume":"62","author":"Xu C","year":"2020","unstructured":"Xu C, Xu L, Ohorodnyk P, Roth M, Chen B, Li S. Contrast agent-free synthesis and segmentation of ischemic heart disease images using progressive sequential causal GANs. Med Image Anal. 2020, 62:101668. 10.1016\/j.media.2020.101668","journal-title":"Med Image Anal"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00897-9","article-title":"Convolutional neural networks for detection of transthyretin amyloidosis in 2D scintigraphy images","volume":"12","author":"Halme HL","year":"2022","unstructured":"Halme HL, Ihalainen T, Suomalainen O, et al.. Convolutional neural networks for detection of transthyretin amyloidosis in 2D scintigraphy images. EJNMMI Res. 2022, 12:27. 10.1186\/s13550-022-00897-9","journal-title":"EJNMMI Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2023.01.014","article-title":"Deep learning on bone scintigraphy to\u00a0detect abnormal cardiac uptake at\u00a0risk of cardiac amyloidosis","volume":"16","author":"Delbarre MA","year":"2023","unstructured":"Delbarre MA, Girardon F, Roquette L, et al.. Deep learning on bone scintigraphy to\u00a0detect abnormal cardiac uptake at\u00a0risk of cardiac amyloidosis. JACC Cardiovasc Imaging. 2023, 16:1085-95. 10.1016\/j.jcmg.2023.01.014","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010319","article-title":"Classification of amyloidosis by model-assisted mass spectrometry-based proteomics","volume":"23","author":"Palstr\u00f8m NB","year":"2021","unstructured":"Palstr\u00f8m NB, Rojek AM, M\u00f8ller HE, et al.. Classification of amyloidosis by model-assisted mass spectrometry-based proteomics. Int J Mol Sci. 2021, 23:10.3390\/ijms23010319","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/bios13040466","article-title":"Non-perturbative identification and subtyping of amyloidosis in human kidney tissue with Raman spectroscopy and machine learning","volume":"13","author":"Kim JH","year":"2023","unstructured":"Kim JH, Zhang C, Sperati CJ, Bagnasco SM, Barman I. Non-perturbative identification and subtyping of amyloidosis in human kidney tissue with Raman spectroscopy and machine learning. Biosensors (Basel). 2023, 13:10.3390\/bios13040466","journal-title":"Biosensors (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2022.100013","article-title":"Machine learning quantification of amyloid deposits in histological images of ligamentum flavum","volume":"13","author":"Wang AY","year":"2022","unstructured":"Wang AY, Sharma V, Saini H, et al.. Machine learning quantification of amyloid deposits in histological images of ligamentum flavum. J Pathol Inform. 2022, 13:100013. 10.1016\/j.jpi.2022.100013","journal-title":"J Pathol Inform"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1159\/000500896","article-title":"Deep learning algorithms for corneal amyloid deposition quantitation in familial amyloidosis","volume":"6","author":"Kessel K","year":"2020","unstructured":"Kessel K, Mattila J, Linder N, Kivel\u00e4 T, Lundin J. Deep learning algorithms for corneal amyloid deposition quantitation in familial amyloidosis. Ocul Oncol Pathol. 2020, 6:58-65. 10.1159\/000500896","journal-title":"Ocul Oncol Pathol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23880-9","article-title":"Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity","volume":"12","author":"Garofalo M","year":"2021","unstructured":"Garofalo M, Piccoli L, Romeo M, et al.. Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity. Nat Commun. 2021, 12:3532. 10.1038\/s41467-021-23880-9","journal-title":"Nat Commun"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-79","article-title":"Using simple artificial intelligence methods for predicting amyloidogenesis in antibodies","volume":"11","author":"David MP","year":"2010","unstructured":"David MP, Concepcion GP, Padlan EA. Using simple artificial intelligence methods for predicting amyloidogenesis in antibodies. BMC Bioinformatics. 2010, 11:79. 10.1186\/1471-2105-11-79","journal-title":"BMC Bioinformatics"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore JD","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al.. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018, 39:2799-806. 10.1093\/eurheartj\/ehx589","journal-title":"Eur Heart J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin\u00a0cardiac amyloidosis and\u00a0risk stratification using a novel\u00a0staging system","volume":"68","author":"Grogan M","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, et al.. Natural history of wild-type transthyretin\u00a0cardiac amyloidosis and\u00a0risk stratification using a novel\u00a0staging system. J Am Coll Cardiol. 2016, 68:1014-20. 10.1016\/j.jacc.2016.06.033","journal-title":"J Am Coll Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri A","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, et al.. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004, 22:3751-7. 10.1200\/JCO.2004.03.029","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri A","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, et al.. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004, 104:1881-7. 10.1182\/blood-2004-01-0390","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar S","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al.. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012, 30:989-95. 10.1200\/JCO.2011.38.5724","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: Results from TOPCAT","volume":"9","author":"Sperry BW","year":"2021","unstructured":"Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: Results from TOPCAT. JACC Heart Fail. 2021, 9:795-802. 10.1016\/j.jchf.2021.06.007","journal-title":"JACC Heart Fail"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19 Suppl 1","author":"Obici L","year":"2012","unstructured":"Obici L, Cortese A, Lozza A, et al.. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012, 19 Suppl 1:34-6. 10.3109\/13506129.2012.678508","journal-title":"Amyloid"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S96893","article-title":"Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study","volume":"9","author":"aus dem Siepen F","year":"2015","unstructured":"aus dem Siepen F, Bauer R, Aurich M, et al.. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther. 2015, 9:6319-25. 10.2147\/DDDT.S96893","journal-title":"Drug Des Devel Ther"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore JD","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al.. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021, 385:493-502. 10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac\u00a0amyloidosis","volume":"6","author":"Giancaterino S","year":"2020","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac\u00a0amyloidosis. JACC Clin Electrophysiol. 2020, 6:351-61. 10.1016\/j.jacep.2020.01.004","journal-title":"JACC Clin Electrophysiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial\u00a0arrhythmias in adults with cardiac\u00a0amyloidosis","volume":"73","author":"El-Am EA","year":"2019","unstructured":"El-Am EA, Dispenzieri A, Melduni RM, et al.. Direct current cardioversion of atrial\u00a0arrhythmias in adults with cardiac\u00a0amyloidosis. J Am Coll Cardiol. 2019, 73:589-97. 10.1016\/j.jacc.2018.10.079","journal-title":"J Am Coll Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology\u00a0in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully PR","year":"2020","unstructured":"Scully PR, Patel KP, Treibel TA, et al.. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology\u00a0in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020, 41:2759-67. 10.1093\/eurheartj\/ehaa170","journal-title":"Eur Heart J"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202303210","article-title":"Cardiac amyloidosis","volume":"176","author":"Bloom MW","year":"2023","unstructured":"Bloom MW, Gorevic PD. Cardiac amyloidosis. Ann Intern Med. 2023, 176:ITC33-48. 10.7326\/AITC202303210","journal-title":"Ann Intern Med"},{"key":"ref59","unstructured":"Creative Commons. Homepage. (2024). Accessed: July 2, 2024: http:\/\/creativecommons.org\/licenses\/by\/4.0\/.."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/267821-cardiac-amyloidosis-a-comprehensive-review-of-pathophysiology-diagnostic-approach-applications-of-artificial-intelligence-and-management-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:31:12Z","timestamp":1719934272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/267821-cardiac-amyloidosis-a-comprehensive-review-of-pathophysiology-diagnostic-approach-applications-of-artificial-intelligence-and-management-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.63673","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}